è	7	
14.4	AIZED	DOTE
<u>ଅ</u> ଧ⁄	ANEK	BO S LLE
- See - 1		

07-2001

## UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. A33626-A 067252.0107

First Inventor Smith et al.

Title RECOMBINANT

\* se<u>e\_at</u>tached

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Express Mail Label No. EK 839 854 822 US

APPLICATION ELEMENTS	ASSISTANT Commissioner for Patents		
See MPEP chapter 600 concerning utility patent application cont	ADDRESS TO: Box Patent Application Washington, DC 20231		
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	7. CD-ROM or CD-R in duplicate, large table or		
Applicant claims small entity status.	Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission		
See 37 CFR 1.27. Specification [Total Pages 74]	(if applicable, all necessary)		
(preferred arrangement set forth below)     Descriptive title of the invention	a. Computer Readable Form (CRF)		
<ul> <li>Cross Reference to Related Applications</li> </ul>	b. Specification Sequence Listing on:		
<ul> <li>Statement Regarding Fed sponsored R &amp; D</li> <li>Reference to sequence listing, a table,</li> </ul>	i.		
or a computer program listing appendix - Background of the Invention	i i. 🗹 paper c. 🗹 Statements verifying identity of above copies		
Brief Summary of the Invention     Brief Description of the Drawings (if filed)	ACCOMPANYING APPLICATION PARTS		
Detailed Description 7	9. Assignment Papers (cover sheet & document(s))		
Claim(s) [Total Sheets Abstract of the Disclosure Total Sheets 1	37 CFR 3.73(b) Statement Power of		
4. Drawing(s) (35 U.S.C. 113) [ Total Sheets 23			
5. Oath or Declaration [Total Pages	Information Disclosure Copies of IDS		
a. Newly executed (original or copy)	Statement (IDS)/PTO-1449 Citations  13. Preliminary Amendment		
b. Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed	Roturn Bossint Bostoned (MRED 503)		
i. DELETION OF INVENTOR(S)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)		
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR	16. Request and Certification under 35 U.S.C. 122		
1.63(d)(2) and 1.33(b). (b)(2)(B)(i). Applicant must attach form PTO/SE or its equivalent.			
6. Application Data Sheet. See 37 CFR 1.76	17. Other:		
18. If a CONTINUING APPLICATION, check appropriate box, and	d supply the requisite information below and in a preliminary amendment.		
or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part	(CIP) of prior application No.: 09/611,419		
Prior application information: Examiner TBA	Group Art Unit: 1653		
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosur	e of the prior application, from which an eath or declaration is supplied under		
The incorporation can only be relied upon when a portion has been in	continuation or divisional application and is hereby incorporated by reference. nadvertently omitted from the submitted application parts.		
	ONDENCE ADDRESS		
Customer Number or Bar Code Label (Insert Customer No. or, Al	ach bar code label here) or Correspondence address below		
Name			
Address			
City	State Zip Code		
Country	Telephone Fax		
Name (Print/Type) Rochelle K. Seide	Registration No. (Attorney/Agent) 32,300		
Signature KOUULL 1 - 1	WW Date 07-20-2001		

## BAKER BOTTS LLP

Addendum Sheet 1

Att Docket #: A33626-A 067252.0107

*Question 4 Addendum 4.a. Drawings are ☐ formal ☑informal
* Question 5 Addendum 5.c. ☐An unsigned oath or declaration is included.
* Question 8 Addendum 8.d. ☐ A sequence submission will follow.
* Question 9 Addendum 9.a. ☑ Assignment documents will follow. 9.b. ☐ Assignment documents have been filed in parent application No.
* Question 11 Addendum 11.a ☐ English translation will follow.
* Question 12 Addendum 12.a  Copies of IDS citations will follow.
* Question 15 Addendum 15.a.☐ Certified copies of priority documents will follow. 15.b.☐ Certified copies of priority documents have been filed in parent application No.
Use the space below for additional information
Sequence Listing enclosed herewith comprises 53 pages.  EK 839 854 877 US
Title (continued): RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN

## BAKER BOTTS LLP

Att Docket #: A33626-A 067252.0107

Addendum Sheet 2 18a. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Divisional Continuation-in-part (CIP) Continuation of prior application No.:\_\_\_\_\_ Prior application information: Group Art Unit: 18b. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation: Divisional Continuation-in-part (CIP) of prior application No.:\_\_\_\_\_ Prior application information: Examiner Group Art Unit: \_\_\_\_\_ 18c. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Divisional Continuation-in-part (CIP) Continuation of prior application No.:\_\_\_\_\_ Prior application information: Examiner Amend the specification by inserting before the first line the sentence(s) "This application is a Continuation Divisional Continuation-in-part (CIP) of: "This application is based upon: , incorporated by reference herein, prior application No.:\_\_\_\_\_ which is a Continuation Divisional Continuation-in-part (CIP) of: which is based upon: , incorporated by reference herein, prior application No.:\_\_ which is a Continuation Divisional Continuation-in-part (CIP) of: which is based upon: , incorporated by reference herein, prior application No.: which is a Continuation Divisional Continuation-in-part (CIP) of: which is based upon: \_\_\_\_\_, incorporated by reference herein, prior application No.:\_\_ which is a Continuation Divisional Continuation-in-part (CIP) of: which is based upon: prior application No.:\_\_\_ \_\_\_ , incorporated by reference herein, Continuation-in-part (CIP) of: which is a Continuation Divisional which is based upon: \_\_\_\_\_, incorporated by reference herein prior application No.:\_\_\_\_ Priority under 35.U.S.C. §119 is claimed based upon the following applications. Foreign Applications: Country: \_\_\_ Filing Date:\_ Country: \_\_\_\_\_ Serial No:\_\_\_\_\_ Filing Date:\_\_\_\_ Filing Date: Country: \_\_\_ Serial No:\_\_\_\_\_ Provisional Applications: Serial No:\_\_\_ Filing Date:\_\_\_\_\_ Serial No:\_\_\_\_\_ Filing Date:\_\_\_\_\_ Serial No:\_\_\_ Filing Date:\_\_\_\_



## FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 2,174

Compl t if Known				
July 20, 2001				
Smith et al.				
A33626-A 067252.0107				
	July 20, 2001 Smith et al.			

METHOD OF PAYMENT FEE CALCULATION (continued	FEE CALCULATION (continued)				
1. The Commissioner is hereby authorized to charge 3. ADDITIONAL FEES					
Deposit Large Small					
Account 02-4377	Fee Paid				
(\$) (\$)	ree Paid				
Account Name  Baker Botts LLP  130 65 Surcharge - late filing fee or oath					
Charge Any Additional Fee Required  50 25 Surcharge - late provisional filing fee of cover sheet	or				
Applicant claims small entity status. 130 130 Non-English specification					
See 37 CFR 1.27  2,520 2,520 For filing a request for ex parte reexar	mination				
2. Payment Enclosed:  920* 920* Requesting publication of SIR prior to Examiner action					
FEE CALCULATION  1,840* 1,840* Requesting publication of SIR after Examiner action					
1. BASIC FILING FEE 110 55 Extension for reply within first month					
Large Entity Small Entity 390 195 Extension for reply within second mon	nth				
Fee Fee Fee Description 890 445 Extension for reply within third month (\$) (\$) Fee Paid					
710 355 Utility filing fee 710 1,390 695 Extension for reply within fourth month	h				
320 160 Design filing fee 1,890 945 Extension for reply within fifth month					
490 245 Plant filing fee 310 155 Notice of Appeal					
710 355 Reissue filing fee 310 155 Filing a brief in support of an appeal					
150 75 Provisional filing fee 270 135 Request for oral hearing					
1,510 1,510 Petition to institute a public use proceed	eding				
SUBTOTAL (1) (\$) 710 110 55 Petition to revive - unavoidable					
2. EXTRA CLAIM FEES 1,240 620 Petition to revive - unintentional					
Fee from Extra Claims below Fee Paid 1,240 620 Utility issue fee (or reissue)					
Total Claims 48 -20** = 28 x 18 = 504 440 220 Design issue fee					
Independent 15 -3** = 12 x 80 = 960 600 300 Plant issue fee					
Multiple Dependent = 130 130 Petitions to the Commissioner					
50 50 Processing fee under 37 CFR 1.17(q)					
Large Entity Small Entity Fee Fee Fee Description 180 180 Submission of Information Disclosure S	Stmt				
(\$) (\$) 40 Recording each patent assignment pe	r				
18 9 Claims in excess of 20 property (times number of properties)					
80 40 Independent claims in excess of 3 710 355 Filing a submission after final rejection (37 CFR § 1.129(a))	·				
270 135 Multiple dependent claim, if not paid 710 355. For each additional invention to be					
80 40 ** Reissue independent claims examined (37 CFR § 1.129(b)) over original patent					
18 9 ** Reissue claims in excess of 20 710 355 Request for Continued Examination (R	RCE)				
and over original patent 900 900 Request for expedited examination					
of a design application  SUBTOTAL (2) (\$) 1,464  Other fee (specify)					
**or number previously paid, if greater, For Reissues, see above Reduced by Basic Filing Fee Paid SUBTOTAL (3)	(\$) 0				
C. Halling Freviously paid, if greater, For Reissues, see above					

				Complete (ii	f applicable)
Name (Printl Type) Rochelle	K. Şeide	Registration No. (Attomey/Agent)	32,300	Telephone	(212) 408-2626
Signature	Wille of	Kelle		Date	July 20, 2001